Literature DB >> 21372562

Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.

Elif Ari1, Yusuf Yilmaz, Alla Elden Kedrah, Yesim Alahdab, Fulya Cakalagaoglu, Hakki Arikan, Hüseyin Kocak, Beyza Macunluoglu, Aydin Atakan, Arzu Kahveci, Ebru Asicioglu, Serhan Tuglular, Cetin Ozener.   

Abstract

BACKGROUND/AIMS: Contrast-induced nephropathy (CIN) remains a leading cause of iatrogenic acute renal failure. Terlipressin, a long-acting analog of vasopressin, may improve renal function. This study aimed to investigate the possible protective effect of terlipressin against the development of experimental CIN in rats.
METHODS: Wistar albino rats (n = 32) were allocated randomly into four equal groups of 8 each, i.e. control, terlipressin, contrast media (CM), and terlipressin plus contrast media (TCM). CIN was induced by intravenous administration of indomethacin (10 mg/kg), N-nitro L-arginine methyl ester (L-NAME, 10 mg/kg, twice at 15 and 30 min), and high-osmolar contrast media meglumine amidotrizoate 60%. Renal function parameters, kidney histology, and tubular expression of vascular endothelial growth factor (VEGF) were determined.
RESULTS: Mean serum creatinine levels were decreased (p < 0.05) and creatinine clearance (p < 0.05) increased in the TCM group compared with the CM group. Notably, rats in the TCM group displayed less tubular necrosis (p < 0.05), medullary congestion (p < 0.05), and a reduced tubular expression of VEGF (p < 0.05) compared with the CM group.
CONCLUSION: These results demonstrate that terlipressin can inhibit the development of CIN.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372562     DOI: 10.1159/000324764

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

1.  Protective effect of salidroside on contrast-induced nephropathy in comparison with N-acetylcysteine and its underlying mechanism.

Authors:  Yue Xing; Ri-bao Wei; Lu Tang; Yue Yang; Xiao-yong Zheng; Zi-cheng Wang; Yu-wei Gao
Journal:  Chin J Integr Med       Date:  2015-04-16       Impact factor: 1.978

2.  A novel contrast-induced acute kidney injury model based on the 5/6-nephrectomy rat and nephrotoxicological evaluation of iohexol and iodixanol in vivo.

Authors:  Tong-qiang Liu; Wei-li Luo; Xiao Tan; Yi Fang; Jing Chen; Hui Zhang; Xiao-fang Yu; Jie-ru Cai; Xiao-qiang Ding
Journal:  Oxid Med Cell Longev       Date:  2014-11-11       Impact factor: 6.543

Review 3.  Histopathological Evaluation of Contrast-Induced Acute Kidney Injury Rodent Models.

Authors:  Norbert Kiss; Péter Hamar
Journal:  Biomed Res Int       Date:  2016-11-16       Impact factor: 3.411

4.  Does Resveratrol Play a Role in Decreasing the Inflammation Associated with Contrast Induced Nephropathy in Rat Model?

Authors:  Yi-Hsin Chen; Yun-Ching Fu; Ming-Ju Wu
Journal:  J Clin Med       Date:  2019-01-27       Impact factor: 4.241

5.  Atorvastatin protects against contrast-induced acute kidney injury via upregulation of endogenous hydrogen sulfide.

Authors:  Lin Yan; Lin Jiaqiong; Guo Yue; Li Xiaoyong; Tan Xuexian; Long Ming; Li Yinglan; Liao Xinxue; Huang Zena
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

6.  A novel contrast-induced acute kidney injury mouse model based on low-osmolar contrast medium.

Authors:  Jiajia Wu; Jianxiao Shen; Wanpeng Wang; Na Jiang; Haijiao Jin; Xiajing Che; Zhaohui Ni; Yan Fang; Shan Mou
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 7.  Drug-induced liver injury: present and future.

Authors:  Ki Tae Suk; Dong Joon Kim
Journal:  Clin Mol Hepatol       Date:  2012-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.